Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379

被引：0
|
作者：
Alvarado, D. [1 ]
Lee, S. [2 ]
Greenlee, E. [2 ]
Ligon, G. F. [1 ]
Lillquist, J. S. [1 ]
Natoli, E. J. [1 ]
Amick, J. [2 ]
Hadari, Y. [1 ]
Schlessinger, J. [2 ]
机构：
[1] Kolltan Pharmaceut Inc, Dept Res, New Haven, CT USA
[2] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70533-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
407
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [1] Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379
    Alvarado, Diego
    Lee, Sangwon
    Greenlee, Etienne
    Ligon, Gwenda F.
    Lillquist, Jay S.
    Natoli, Edward J.
    LaVallee, Theresa M.
    Schlessinger, Joseph
    CANCER RESEARCH, 2015, 75
  • [2] An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
    Schoeberl, Birgit
    Faber, Anthony C.
    Li, Danan
    Liang, Mei-Chih
    Crosby, Katherine
    Onsum, Matthew
    Burenkova, Olga
    Pace, Emily
    Walton, Zandra
    Nie, Lin
    Fulgham, Aaron
    Song, Youngchul
    Nielsen, Ulrik B.
    Engelman, Jeffrey A.
    Wong, Kwok-Kin
    CANCER RESEARCH, 2010, 70 (06) : 2485 - 2494
  • [3] AV-203, a humanized ERBB3 inhibitory antibody inhibits ligand-dependent and ligand-independent ERBB3 signaling in vitro and in vivo
    Vincent, Sylvie
    Fleet, Christina
    Bottega, Steven
    McIntosh, Donna
    Winston, William
    Chen, Ting
    Tyler, Steven
    Meetze, Kristan
    Weiler, Solly
    Gyuris, Jeno
    CANCER RESEARCH, 2012, 72
  • [4] Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN
    Ligon, Gwenda F.
    Lillquist, Jay S.
    Seibel, Scott B.
    Wallweber, Jerry
    Neumeister, Veronique
    Rimm, David L.
    LaVallee, Theresa M.
    Alvarado, Diego
    CANCER RESEARCH, 2016, 76
  • [5] Role of Nuclear ErbB3 localization in regulating ligand-dependent ErbB2-ErbB3 heterodimer activation and downstream targets in prostate cancer
    Jathal, Maitreyee K.
    Mudryj, Maria M.
    Ghosh, Paramita M.
    CANCER RESEARCH, 2024, 84 (06)
  • [6] Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN
    Alvarado, Diego
    Wallweber, Jerry
    Seibel, Scott
    Chenna, Ahmed
    Ravanera, Roy
    Huang, Weidong
    Stathas, David
    Theobald, Paul
    LaVallee, Theresa M.
    CANCER RESEARCH, 2015, 75
  • [7] A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers
    LoRusso, P.
    LaVallee, T.
    Kimmel, L.
    Lubeski, C.
    Gedrich, R.
    Sidor, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 71 - 71
  • [8] ErbB3 is required for Src induced ligand-independent activation of ErbB2
    Herynk, Matthew H.
    Beyer, Amanda
    Fuqua, Suzanne Aw
    CANCER RESEARCH, 2006, 66 (08)
  • [9] A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.
    Bauer, Todd Michael
    Infante, Jeffrey R.
    Eder, Joseph Paul
    LoRusso, Patricia
    LaVallee, Theresa
    Gedrich, Rich
    Sidor, Carolyn
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling
    Zhang, Qian
    Park, Euisun
    Kani, Kian
    Landgraf, Ralf
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (33) : 13237 - 13242
12345